Healthcare AI Startup · Agent Unfolded
DeepScribe
Ambient AI Operating System for Clinical Documentation and Oncology Workflows
San Francisco, California, United States
DeepScribe develops ambient AI technology that listens to clinician-patient conversations and turns them into structured clinical documentation. Its platform has expanded beyond medical scribing into pre-visit preparation, medical coding and specialty-specific workflows, with a strong focus on community oncology.
Company icon sourced from DeepScribe’s website domain
Company overview
DeepScribe is a healthcare technology company developing ambient AI tools for clinical documentation and administrative workflows. Its technology captures natural conversations between clinicians and patients, identifies medically relevant information and prepares structured notes for electronic health record (EHR) systems.
The company was founded in 2017. Its early product focused on reducing the time clinicians spend writing medical notes and entering information into patient records. Over time, DeepScribe expanded its capabilities from transcription and note generation into a broader platform designed to support clinical workflows before, during and after patient visits.
DeepScribe now describes its platform as an Ambient Operating System for healthcare. Its current strategy places particular emphasis on oncology, where complex treatment histories, medications, laboratory results and coordination between care teams create substantial documentation and information-management demands.
The company says its technology is deployed across more than 1,500 healthcare organizations. Its website also reports more than 2,800 clinics and health systems served and over eight million visits captured. These are company-reported figures.
Products and technology
AI Medical Scribe: DeepScribe’s core product captures clinician-patient conversations and generates structured clinical notes. It is designed to preserve the relevant medical details of an encounter while reducing manual documentation.
Ambient Operating System: The broader platform connects documentation with information retrieval, coding and other clinical workflows. It is designed to provide support across the patient visit rather than only generating a transcript after the conversation.
SmartPrep: SmartPrep prepares a contextual summary before a patient visit. It brings together relevant information from the patient’s medical record, including previous notes, laboratory results, imaging, medications and diagnoses.
AI Coding: DeepScribe’s coding capabilities help identify diagnoses and support clinical coding workflows. The company positions this product as a way to improve coding completeness and reduce manual administrative work.
Customization Studio: The platform adapts clinical notes to individual provider preferences. Clinicians can customize documentation formats, language and structure so generated notes fit their established workflows.
DeepScribe Embedded: DeepScribe can be accessed from within supported EHR environments, including OncoEMR and iKnowMed. The embedded experience is designed to reduce the need to move between separate applications.
Specialty-specific AI: DeepScribe develops models and workflows for complex medical specialties. Its current website places a particular emphasis on oncology, where clinical context and detailed patient histories are important to accurate documentation.
The company combines speech recognition, natural language processing, machine learning and clinical context retrieval. Its system is designed to distinguish medically relevant information from ordinary conversation and organize the result into a clinician-ready record.
Funding history
DeepScribe has raised several rounds of venture financing since its early development. Its $30 million Series A was announced in January 2022. A later Series B financing of approximately $24 million was recorded in October 2023 by funding databases.
| Round | Amount | Announced | Lead / reported investors |
|---|---|---|---|
| Seed | $5.2 million | May 2021 | Sequoia and existing investors |
| Series A | $30 million | January 2022 | Index Ventures |
| Series B | Approximately $24 million | October 2023 | Reported investor group includes Sequoia and existing backers |
The $30 million Series A was led by Index Ventures, with participation from Bee Partners, Stage 2 Capital, 1984 Ventures and angel investors including Alex Wang and Dylan Field.
The October 2023 Series B amount and investor details are reported in third-party funding databases rather than a detailed public company announcement. Bee Partners’ portfolio page has also described DeepScribe as having raised $50 million to date. Funding databases do not consistently report the same cumulative figure.
Based on the $5.2 million seed, $30 million Series A and approximately $24 million Series B entries, the disclosed round amounts add up to approximately $59.2 million. This is a calculated total from reported rounds, not a company-confirmed lifetime funding figure.
DeepScribe’s valuation has not been publicly confirmed. Third-party enterprise-value estimates should not be treated as a disclosed financing valuation.
Founders and leadership
Akilesh Bapu · Co-Founder: Akilesh Bapu co-founded DeepScribe after seeing the administrative burden that clinical documentation placed on physicians. His father’s work as an oncologist helped shape the original idea for an ambient AI system that could document natural patient conversations.
Matthew Ko · Co-Founder and CEO: Matthew Ko is identified as CEO and co-founder on DeepScribe’s current About page. He has described the company’s mission as helping clinicians spend more time with patients and less time on administrative documentation.
Kairui Zeng · Co-Founder: Kairui Zeng is also identified as a co-founder in company and funding records. Public sources do not consistently describe his current operating role.
DeepScribe’s early leadership and founder team are documented in its funding coverage and investor profiles. The company does not publish a complete current executive leadership roster on its public About page.
Investors
DeepScribe has attracted investment from healthcare-focused funds, early-stage venture firms and technology investors. The following firms and individuals appear in company announcements, investor portfolio pages and funding records.
Other investors and participants identified in the January 2022 Series A announcement include Alex Wang, founder of Scale AI, and Dylan Field, co-founder of Figma. Plug and Play and Berkeley SkyDeck also appear in DeepScribe’s early funding history.
Customers and healthcare partnerships
DeepScribe’s current website highlights adoption across oncology organizations and healthcare networks. Its named customers and clinical organizations include:
These organizations are highlighted on DeepScribe’s website as part of its oncology customer and provider network. The list should not be interpreted as a complete list of customers or as confirmation that every organization uses every product module.
Traction and company progress
DeepScribe reports that its Ambient Operating System is used in more than 1,500 healthcare organizations. Its website separately lists more than 2,800 clinics and health systems served and over eight million visits captured.
The company also reports a 99.92% note satisfaction rating. In its 2025 KLAS Spotlight Report coverage, DeepScribe highlights an overall performance score of 98.8 out of 100.
Its oncology focus is a central part of its current growth strategy. The company says its platform is used across 90% of community oncology centers, positioning it as a specialist provider in a complex clinical segment.
Traction disclosure: Organization counts, visit volumes, satisfaction figures and oncology adoption claims are based on DeepScribe’s published website and company materials. They have not been independently audited for this profile.
Security and compliance
DeepScribe works with protected health information and integrates into clinical environments, making privacy, security and data handling important parts of its product offering.
The company provides security and compliance information for healthcare organizations evaluating its platform. Its current website highlights secure and compliant workflows, but the specific certification details and audit documentation should be confirmed directly with DeepScribe during procurement.
Healthcare providers should evaluate the company’s business associate agreement, data retention terms, access controls, encryption practices, audit capabilities and integration-level permissions before deployment.
Verification note: This profile does not independently certify DeepScribe’s security controls or regulatory compliance. Request current audit reports and contractual documentation from the company.
Frequently asked questions
What does DeepScribe do?
DeepScribe develops ambient AI software that captures clinician-patient conversations and generates structured medical documentation. Its platform also supports pre-visit preparation, medical coding and specialty-specific clinical workflows.
How much funding has DeepScribe raised?
Reported funding rounds include a $5.2 million seed round, a $30 million Series A and an approximately $24 million Series B. These amounts add up to approximately $59.2 million, although third-party funding records vary and the company has not confirmed a single cumulative total.
Who founded DeepScribe?
DeepScribe was founded by Akilesh Bapu, Matthew Ko and Kairui Zeng. Matthew Ko is identified as CEO and co-founder on the company’s current About page.
Who invested in DeepScribe?
Reported investors include Index Ventures, Sequoia Capital, Bee Partners, 1984 Ventures, Foothill Ventures, Stage 2 Capital, Industry Ventures, Wavemaker and Plug and Play.
What is DeepScribe’s main product?
Its core product is an AI medical scribe that converts clinician-patient conversations into structured clinical notes. Its wider Ambient Operating System includes SmartPrep, AI Coding and customization tools.
Does DeepScribe focus on oncology?
Yes. DeepScribe currently positions itself strongly around community oncology, where it supports documentation, patient context retrieval, coding and related clinical workflows.
Where is DeepScribe headquartered?
DeepScribe is headquartered in San Francisco, California, United States.
What is DeepScribe’s valuation?
DeepScribe’s valuation has not been publicly confirmed. Third-party enterprise-value estimates should not be treated as an official funding valuation.
Corrections or updates? If you spot an error or have information that should be updated in this profile, please contact hello@agentunfolded.com.
← Explore the AI Startup Directory